HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: M700590-MCP200v1 7/7/1214    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Glossary Google Scholar Articles by Thorsen, K. Articles by Ørntoft, T. F. PubMed PubMed Citation Articles by Thorsen, K. Articles by Ørntoft, T. F. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 7:1214-1224, 2008.
© 2008 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Research

Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis^*,S

Kasper Thorsen, Karina D. Sørensen, Anne Sofie Brems-Eskildsen, Charlotte Modin, Mette Gaustadnes, Anne-Mette K. Hein, Mogens Kruhøffer, Søren Laurberg, Michael Borre^¶, Kai Wang^||, Søren Brunak^||, Adrian R. Krainer^**, Niels Tørring, Lars Dyrskjøt, Claus L. Andersen and Torben F. Ørntoft^,

From the Molecular Diagnostic Laboratory, Department of Clinical Biochemistry and ^¶ Department of Urology, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark, Department of Surgery P, Aarhus University Hospital, Aarhus Hospital, DK-8000 Aarhus C, Denmark, ^|| Center for Biological Sequence Analysis, BioCentrum-DTU, Technical University of Denmark, DK-2800 Lyngby, Denmark, and ^** Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724

Alternative splicing enhances proteome diversity and modulates cancer-associated proteins. To identify tissue- and tumor-specific alternative splicing, we used the GeneChip Human Exon 1.0 ST Array to measure whole-genome exon expression in 102 normal and cancer tissue samples of different stages from colon, urinary bladder, and prostate. We identified 2069 candidate alternative splicing events between normal tissue samples from colon, bladder, and prostate and selected 15 splicing events for RT-PCR validation, 10 of which were successfully validated by RT-PCR and sequencing. Furthermore 23, 19, and 18 candidate tumor-specific splicing alterations in colon, bladder, and prostate, respectively, were selected for RT-PCR validation on an independent set of 81 normal and tumor tissue samples. In total, seven genes with tumor-specific splice variants were identified (ACTN1, CALD1, COL6A3, LRRFIP2, PIK4CB, TPM1, and VCL). The validated tumor-specific splicing alterations were highly consistent, enabling clear separation of normal and cancer samples and in some cases even of different tumor stages. A subset of the tumor-specific splicing alterations (ACTN1, CALD1, and VCL) was found in all three organs and may represent general cancer-related splicing events. In silico protein predictions suggest that the identified cancer-specific splice variants encode proteins with potentially altered functions, indicating that they may be involved in pathogenesis and hence represent novel therapeutic targets. In conclusion, we identified and validated alternative splicing between normal tissue samples from colon, bladder, and prostate in addition to cancer-specific splicing events in colon, bladder, and prostate cancer that may have diagnostic and prognostic implications.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?